Loading…
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection
Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytot...
Saved in:
| Published in: | The New microbiologica 2017-07, Vol.40 (3), p.218-220 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 220 |
| container_issue | 3 |
| container_start_page | 218 |
| container_title | The New microbiologica |
| container_volume | 40 |
| creator | Odolini, Silvia Lanza, Paola Angiola, Angiola Zaltron, Serena Urbinati, Lucia Vavassori, Andrea Nasta, Paola Festa, Elena Gargiulo, Franco Rodella, Anna Caruso, Arnaldo Casari, Salvatore Castelli, Francesco Viganò, Mauro |
| description | Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC. |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899792231</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2103699070</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-89edb9a6e910ee3085e4c71ae0d55af4908a9022761b9ffdaecc7f766ef51fe03</originalsourceid><addsrcrecordid>eNplUE1PwzAMzQHEprG_gCJx4VIpH2vTHGEChjSJC5yrNHW0TG1SknSIP8DvJoNxAV_s9_z8bPkMzSlltBCU1zO0jHFPclQlZZJdoBmry9ygfI4-NzCqZJON-A4fbJgiDqB0sofMeoeVSRAwGANHDnD0xsd2ykqsXIeDbVWurcMpj6UBXMIZKHw0PYJ3m3bYaz31Ce_-rbLu29e7S3RuVB9hecoL9Ppw_7LeFNvnx6f17bYYGZepqCV0rVQVSEoAOKlLWGlBFZCuLJVZSVIrSRgTFW2lMZ0CrYURVQWmpAYIX6CbH98x-LcJYmoGGzX0vXLgp9jQWkohGeM0S6__SPd-Ci5f1zBKeCUlEUfDq5NqagfomjHYQYWP5vfD_AvtmnoL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2103699070</pqid></control><display><type>article</type><title>Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection</title><source>EZB Electronic Journals Library</source><creator>Odolini, Silvia ; Lanza, Paola ; Angiola, Angiola ; Zaltron, Serena ; Urbinati, Lucia ; Vavassori, Andrea ; Nasta, Paola ; Festa, Elena ; Gargiulo, Franco ; Rodella, Anna ; Caruso, Arnaldo ; Casari, Salvatore ; Castelli, Francesco ; Viganò, Mauro</creator><creatorcontrib>Odolini, Silvia ; Lanza, Paola ; Angiola, Angiola ; Zaltron, Serena ; Urbinati, Lucia ; Vavassori, Andrea ; Nasta, Paola ; Festa, Elena ; Gargiulo, Franco ; Rodella, Anna ; Caruso, Arnaldo ; Casari, Salvatore ; Castelli, Francesco ; Viganò, Mauro</creatorcontrib><description>Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC.</description><identifier>ISSN: 1121-7138</identifier><identifier>PMID: 28513813</identifier><language>eng</language><publisher>Italy: Edizioni Medico Scientifiche</publisher><subject>Activation ; Aged ; Anti-Inflammatory Agents - administration & dosage ; Antibodies ; Antiviral agents ; Antiviral Agents - therapeutic use ; Cryoglobulinemia - complications ; Cryoglobulinemia - drug therapy ; Cytotoxicity ; Deoxyribonucleic acid ; DNA ; DNA, Viral - blood ; Female ; Genotypes ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hepatitis ; Hepatitis B ; Hepatitis B - complications ; Hepatitis B - drug therapy ; Hepatitis B Antibodies - blood ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus - genetics ; Hepatitis C ; Hepatitis C - complications ; Hepatitis C - drug therapy ; Humans ; Immunologic Factors - therapeutic use ; Immunosuppressive agents ; Infections ; Interferon ; Liver ; Patients ; Prednisolone - administration & dosage ; Recurrence ; Ribavirin ; Ribavirin - therapeutic use ; Rituximab - therapeutic use ; Sofosbuvir - therapeutic use ; Viral Load ; Viruses</subject><ispartof>The New microbiologica, 2017-07, Vol.40 (3), p.218-220</ispartof><rights>Copyright Edizioni Medico Scientifiche Jul 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28513813$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Odolini, Silvia</creatorcontrib><creatorcontrib>Lanza, Paola</creatorcontrib><creatorcontrib>Angiola, Angiola</creatorcontrib><creatorcontrib>Zaltron, Serena</creatorcontrib><creatorcontrib>Urbinati, Lucia</creatorcontrib><creatorcontrib>Vavassori, Andrea</creatorcontrib><creatorcontrib>Nasta, Paola</creatorcontrib><creatorcontrib>Festa, Elena</creatorcontrib><creatorcontrib>Gargiulo, Franco</creatorcontrib><creatorcontrib>Rodella, Anna</creatorcontrib><creatorcontrib>Caruso, Arnaldo</creatorcontrib><creatorcontrib>Casari, Salvatore</creatorcontrib><creatorcontrib>Castelli, Francesco</creatorcontrib><creatorcontrib>Viganò, Mauro</creatorcontrib><title>Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection</title><title>The New microbiologica</title><addtitle>New Microbiol</addtitle><description>Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC.</description><subject>Activation</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Antibodies</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cryoglobulinemia - complications</subject><subject>Cryoglobulinemia - drug therapy</subject><subject>Cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Genotypes</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - drug therapy</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunosuppressive agents</subject><subject>Infections</subject><subject>Interferon</subject><subject>Liver</subject><subject>Patients</subject><subject>Prednisolone - administration & dosage</subject><subject>Recurrence</subject><subject>Ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Rituximab - therapeutic use</subject><subject>Sofosbuvir - therapeutic use</subject><subject>Viral Load</subject><subject>Viruses</subject><issn>1121-7138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNplUE1PwzAMzQHEprG_gCJx4VIpH2vTHGEChjSJC5yrNHW0TG1SknSIP8DvJoNxAV_s9_z8bPkMzSlltBCU1zO0jHFPclQlZZJdoBmry9ygfI4-NzCqZJON-A4fbJgiDqB0sofMeoeVSRAwGANHDnD0xsd2ykqsXIeDbVWurcMpj6UBXMIZKHw0PYJ3m3bYaz31Ce_-rbLu29e7S3RuVB9hecoL9Ppw_7LeFNvnx6f17bYYGZepqCV0rVQVSEoAOKlLWGlBFZCuLJVZSVIrSRgTFW2lMZ0CrYURVQWmpAYIX6CbH98x-LcJYmoGGzX0vXLgp9jQWkohGeM0S6__SPd-Ci5f1zBKeCUlEUfDq5NqagfomjHYQYWP5vfD_AvtmnoL</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Odolini, Silvia</creator><creator>Lanza, Paola</creator><creator>Angiola, Angiola</creator><creator>Zaltron, Serena</creator><creator>Urbinati, Lucia</creator><creator>Vavassori, Andrea</creator><creator>Nasta, Paola</creator><creator>Festa, Elena</creator><creator>Gargiulo, Franco</creator><creator>Rodella, Anna</creator><creator>Caruso, Arnaldo</creator><creator>Casari, Salvatore</creator><creator>Castelli, Francesco</creator><creator>Viganò, Mauro</creator><general>Edizioni Medico Scientifiche</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201707</creationdate><title>Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection</title><author>Odolini, Silvia ; Lanza, Paola ; Angiola, Angiola ; Zaltron, Serena ; Urbinati, Lucia ; Vavassori, Andrea ; Nasta, Paola ; Festa, Elena ; Gargiulo, Franco ; Rodella, Anna ; Caruso, Arnaldo ; Casari, Salvatore ; Castelli, Francesco ; Viganò, Mauro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-89edb9a6e910ee3085e4c71ae0d55af4908a9022761b9ffdaecc7f766ef51fe03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Activation</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Antibodies</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cryoglobulinemia - complications</topic><topic>Cryoglobulinemia - drug therapy</topic><topic>Cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Genotypes</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - drug therapy</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunosuppressive agents</topic><topic>Infections</topic><topic>Interferon</topic><topic>Liver</topic><topic>Patients</topic><topic>Prednisolone - administration & dosage</topic><topic>Recurrence</topic><topic>Ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Rituximab - therapeutic use</topic><topic>Sofosbuvir - therapeutic use</topic><topic>Viral Load</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Odolini, Silvia</creatorcontrib><creatorcontrib>Lanza, Paola</creatorcontrib><creatorcontrib>Angiola, Angiola</creatorcontrib><creatorcontrib>Zaltron, Serena</creatorcontrib><creatorcontrib>Urbinati, Lucia</creatorcontrib><creatorcontrib>Vavassori, Andrea</creatorcontrib><creatorcontrib>Nasta, Paola</creatorcontrib><creatorcontrib>Festa, Elena</creatorcontrib><creatorcontrib>Gargiulo, Franco</creatorcontrib><creatorcontrib>Rodella, Anna</creatorcontrib><creatorcontrib>Caruso, Arnaldo</creatorcontrib><creatorcontrib>Casari, Salvatore</creatorcontrib><creatorcontrib>Castelli, Francesco</creatorcontrib><creatorcontrib>Viganò, Mauro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>The New microbiologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Odolini, Silvia</au><au>Lanza, Paola</au><au>Angiola, Angiola</au><au>Zaltron, Serena</au><au>Urbinati, Lucia</au><au>Vavassori, Andrea</au><au>Nasta, Paola</au><au>Festa, Elena</au><au>Gargiulo, Franco</au><au>Rodella, Anna</au><au>Caruso, Arnaldo</au><au>Casari, Salvatore</au><au>Castelli, Francesco</au><au>Viganò, Mauro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection</atitle><jtitle>The New microbiologica</jtitle><addtitle>New Microbiol</addtitle><date>2017-07</date><risdate>2017</risdate><volume>40</volume><issue>3</issue><spage>218</spage><epage>220</epage><pages>218-220</pages><issn>1121-7138</issn><abstract>Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC.</abstract><cop>Italy</cop><pub>Edizioni Medico Scientifiche</pub><pmid>28513813</pmid><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1121-7138 |
| ispartof | The New microbiologica, 2017-07, Vol.40 (3), p.218-220 |
| issn | 1121-7138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1899792231 |
| source | EZB Electronic Journals Library |
| subjects | Activation Aged Anti-Inflammatory Agents - administration & dosage Antibodies Antiviral agents Antiviral Agents - therapeutic use Cryoglobulinemia - complications Cryoglobulinemia - drug therapy Cytotoxicity Deoxyribonucleic acid DNA DNA, Viral - blood Female Genotypes Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis Hepatitis B Hepatitis B - complications Hepatitis B - drug therapy Hepatitis B Antibodies - blood Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Hepatitis C Hepatitis C - complications Hepatitis C - drug therapy Humans Immunologic Factors - therapeutic use Immunosuppressive agents Infections Interferon Liver Patients Prednisolone - administration & dosage Recurrence Ribavirin Ribavirin - therapeutic use Rituximab - therapeutic use Sofosbuvir - therapeutic use Viral Load Viruses |
| title | Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A58%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20virus%20reactivation%20after%20effective%20sofosbuvir%20and%20ribavirin%20treatment%20in%20a%20patient%20with%20occult%20hepatitis%20B%20virus%20infection&rft.jtitle=The%20New%20microbiologica&rft.au=Odolini,%20Silvia&rft.date=2017-07&rft.volume=40&rft.issue=3&rft.spage=218&rft.epage=220&rft.pages=218-220&rft.issn=1121-7138&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2103699070%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p239t-89edb9a6e910ee3085e4c71ae0d55af4908a9022761b9ffdaecc7f766ef51fe03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2103699070&rft_id=info:pmid/28513813&rfr_iscdi=true |